Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.55 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | EHMT1 | Q9H9B1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5422628 | 0.98 | HRH3 (0.54) | HRH3HTR2ASIGMAR1KCNH2HTR1A | |
| SCHEMBL5162948 | 0.79 | HRH3 (0.72) | HRH3HTR2ASIGMAR1KCNH2POLB | |
| SCHEMBL6992013 | 0.74 | POLB (0.68) | HTR2AEHMT2POLBEHMT1 | |
| SCHEMBL2076533 | 0.74 | MAPT (0.53) | HRH3HTR2ASIGMAR1KCNH2EHMT2 | |
| SCHEMBL5430861 | 0.73 | HRH3 (0.43) | HRH3HTR2ASIGMAR1KCNH2HTR1A | |
| SCHEMBL5430853 | 0.73 | HRH3 (0.43) | HRH3HTR2ASIGMAR1KCNH2HTR1A | |
| SCHEMBL311021 | 0.72 | HTR2A (0.57) | HRH3HTR2ASIGMAR1KCNH2HTR1A | |
| SCHEMBL14755492 | 0.72 | HRH3 (0.58) | HRH3HTR2ASIGMAR1KCNH2HTR1A | |
| SCHEMBL22254610 | 0.71 | HRH3 (0.49) | HRH3HTR2ASIGMAR1KCNH2HTR1A | |
| SCHEMBL2228812 | 0.70 | SIGMAR1 (0.59) | HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070044254-A1 | Novel 2,6-disubstituted primary para-phenylenediamines and process for their use in the oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2007-03-01 | — | — | US | claimed |
| EP-1757579-A1 | Primary 2,6-disubstituted para-phenylenediamines and their uses for dyeing keratin fibres | L'Oréal (FR) | 2007-02-28 | — | — | EP | claimed |
| US-20070044254-A1 | Novel 2,6-disubstituted primary para-phenylenediamines and process for their use in the oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2007-03-01 | — | — | US | disclosed |
| US-20070044254-A1 | Novel 2,6-disubstituted primary para-phenylenediamines and process for their use in the oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2007-03-01 | — | — | US | disclosed |
| US-20070044254-A1 | Novel 2,6-disubstituted primary para-phenylenediamines and process for their use in the oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2007-03-01 | — | — | US | disclosed |
| EP-1757579-A1 | Primary 2,6-disubstituted para-phenylenediamines and their uses for dyeing keratin fibres | L'Oréal (FR) | 2007-02-28 | — | — | EP | disclosed |
| EP-1757579-A1 | Primary 2,6-disubstituted para-phenylenediamines and their uses for dyeing keratin fibres | L'Oréal (FR) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070044254-A1 | Novel 2,6-disubstituted primary para-phenylenediamines and process for their use in the oxidation dyeing of keratin fibers | KRT18, DSP, CDC73 | HRH3 1245/4885HTR2A 3762/4885SIGMAR1 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.